N-(4-bromophenyl)-2-(3-methyl-2H-indazol-5-yl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-amine
C25H25BrN8 — CID 171354778
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(4-bromophenyl)-2-(3-methyl-2H-indazol-5-yl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-amine
N-(4-bromophenyl)-2-(3-methyl-2H-indazol-5-yl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-amine (PubChem CID 171354778) has the molecular formula C25H25BrN8 and a molecular weight of 517.44 g/mol. Its IUPAC name is N-(4-bromophenyl)-2-(3-methyl-2H-indazol-5-yl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-amine.
Molecular Properties
| Compound Name | N-(4-bromophenyl)-2-(3-methyl-2H-indazol-5-yl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-amine |
|---|---|
| PubChem CID | 171354778 |
| Molecular Formula | C25H25BrN8 |
| Molecular Weight | 517.44 g/mol |
| Exact Mass | 516.14 |
| IUPAC Name | N-(4-bromophenyl)-2-(3-methyl-2H-indazol-5-yl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-amine |
| SMILES | Cc1[nH]nc2ccc(-c3nc4cnc(N5CCN(C)CC5)cn4c3Nc3ccc(Br)cc3)cc12 |
| InChI | InChI=1S/C25H25BrN8/c1-16-20-13-17(3-8-21(20)31-30-16)24-25(28-19-6-4-18(26)5-7-19)34-15-23(27-14-22(34)29-24)33-11-9-32(2)10-12-33/h3-8,13-15,28H,9-12H2,1-2H3,(H,30,31) |
| InChIKey | BCRDUNKQIPRBII-UHFFFAOYSA-N |
| XLogP | 4.84 |
| TPSA | 77.38 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 517.44 |
| LogP ≤ 5 | 4.84 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 171354778 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.